We determined that different portions of the tumor demonstrated variability in drug response, with clinically semi-active and active DSS3 [32] scores for trametinib (a MEK 1/2 inhibitor) and everolimus (an mTOR inhibitor) in the first contrast-enhancing organoids and the tumor–brain interface. Here, MTOR is linked to neoplasm.